Record Details

A CLINICAL STUDY ON DEXMEDETOMIDINE AS A SEDATIVE AND ITS REVERSAL WITH YOHIMBINE IN DOGS

KrishiKosh

View Archive Info
 
 
Field Value
 
Title A CLINICAL STUDY ON DEXMEDETOMIDINE AS A SEDATIVE AND ITS REVERSAL WITH YOHIMBINE IN DOGS
 
Creator ROUTHU SUREKHA
 
Contributor Dr. E.L. CHANDRA SEKHAR
 
Subject A CLINICAL STUDY ON DEXMEDETOMIDINE AS A SEDATIVE AND ITS REVERSAL WITH YOHIMBINE IN DOGS
 
Description The present study was carried out on 12 clinical cases of dogs of either sex and different
age groups presented for minor surgical manipulations or for other reasons that required
chemical restraint. The dogs were randomly divided into two Groups of six animals each. All
were administered atropine sulphate prior to sedation.
In all the dogs of the two groups dexmedetomidine was administered intravenously at the
dose rate of 20g/kg body weight. The dogs of group I were allowed to recover on their own
without any reversal agent, where as for dogs of group II, yohimbine was administered
intravenously at the dose rate of 0.25mg/kg body weight to reverse dexmedetomidine sedation.
The results of the present clinical study revealed that the average time taken for induction
of sedation following the intravenous administration of dexmedetomidine was 6.17 1.14
minutes, 5.83 0.48 minutes in the dogs of group I and II respectively. The duration of sedation
in group I ranged from 30-35 minutes with a mean duration time of 33.17 1.01 minutes. In the
dogs of group II at the end of 15 minutes sedation was reversed with yohimbine. In the dogs of
group I, recovery took 106.67 4.95 minutes, with a range of 90-120 minutes. On the contrary,
in the dogs of group II with yohimbine hydrochloride as a reversal agent, the dogs were aroused
from the dexmedetomidine sedation within 10-15 minutes with a mean duration time of 12.83
1.04 minutes. The difference in the time intervals between the groups I and II has undoubtedly
proved that reversal of dexmedetomidine sedation was achieved by the drug i.e. yohimbine
hydrochloride.
The results showed significant difference in the rectal temperature, heart rate, respiratory
rate during dexmedetomidine sedation, when compared among the three time intervals and two
groups. In the dogs of group I, where no reversal was employed, the rectal temperature, heart
rate and respiratory rates returned back to near normalcy by the end of observation period, when
the dogs recovered from dexmedetomidine induced sedation. In the dogs of group II there was
improvement in the three parameters were observed within 5-10 minutes after administration of
reversal agent i.e. yohimbine hydrochloride.
Hematological examination revealed that there were no significant differences in the
various parameters like TEC, TLC, Hb, PCV, DLC etc., in any of the two groups. Biochemical
parameters like AST, ALT, BUN and Serum creatinine remained within the normal limits in all
the dogs of the two groups. This underscored the fact that all the dexmedetomidine sedation
protocols studied were safe and uneventful.
Electrocardiographic studies in the dogs of two groups revealed no abnormalities in the
sizes of P, QRS or T waves. No changes in the cardiac axis were recorded. No arrhythmias of
any kind were recorded in any animals of two groups.
From the results of the present study the induction time for sedation with
dexmedetomidine in dogs was found to be 6.16 1.14 minutes with a range of 5-8 minutes in all
the dogs across the two groups .The sedative effects of dexmedetomidine could be effectively
reversed by intravenous administration of yohimbine hydrochloride at the dose rate of 0.25
mg/kg body weight. The time taken for reversal using yohimbine hydrochloride was found to be
12.83 1.04 minutes with a range of 10-15 minutes. Pre-medication with atropine and sedation
with dexmedetomidine at the dose rate of 20g/kg body weight intravenously and its reversal
with yohimbine hydrochloride at the dose rate of 0.25 mg/kg body weight intravenously tested or
with natural recovery resulted in minimal changes in the physiological, biochemical or
electrocardiographic parameter studied. It was finally concluded that dexmedetomidine can be
safely and effectively used as a sedative, analgesic and muscle relaxant in dogs. Its reversal
using yohimbine was also concluded to be safe for use in dogs.
CHAPTE
 
Date 2017-01-03T15:28:28Z
2017-01-03T15:28:28Z
2015-05-12
 
Identifier http://krishikosh.egranth.ac.in/handle/1/94216
 
Relation D;418
 
Format application/pdf
 
Publisher PVNR TVU